Pharsight

Norliqva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458095 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(16 years from now)

US11723866 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(16 years from now)

US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(16 years from now)

Norliqva is owned by Cmp Dev Llc.

Norliqva contains Amlodipine Besylate.

Norliqva has a total of 3 drug patents out of which 0 drug patents have expired.

Norliqva was authorised for market use on 24 February, 2022.

Norliqva is available in solution;oral dosage forms.

Norliqva can be used as norliqva is indicated for the symptomatic treatment of chronic stable angina, norliqva is indicated for the treatment of confirmed or suspected vasospastic angina.

The generics of Norliqva are possible to be released after 24 February, 2041.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina; Norliqva is indicated for the symptomatic treatment of chronic stable angina

Dosage: SOLUTION;ORAL

More Information on Dosage

NORLIQVA family patents

Family Patents